New Republic Capital LLC Buys Shares of 26,471 Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

New Republic Capital LLC purchased a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 26,471 shares of the company’s stock, valued at approximately $179,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. ARK Investment Management LLC grew its position in Recursion Pharmaceuticals by 16.4% in the third quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock worth $215,949,000 after acquiring an additional 4,626,268 shares in the last quarter. State Street Corp lifted its stake in shares of Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after purchasing an additional 4,120,685 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Recursion Pharmaceuticals by 13.7% in the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after purchasing an additional 656,003 shares in the last quarter. Institute for Wealth Management LLC. acquired a new position in Recursion Pharmaceuticals during the fourth quarter worth $3,928,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in Recursion Pharmaceuticals by 17.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock valued at $12,789,000 after buying an additional 288,926 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Stock Up 0.1 %

RXRX stock opened at $7.66 on Wednesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The company has a 50-day moving average of $7.16 and a two-hundred day moving average of $6.88. The stock has a market capitalization of $2.99 billion, a price-to-earnings ratio of -5.01 and a beta of 0.86. Recursion Pharmaceuticals, Inc. has a 52-week low of $5.60 and a 52-week high of $15.74.

Wall Street Analyst Weigh In

RXRX has been the subject of several recent analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. KeyCorp decreased their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.